Home/ Stocks/ VTVT

vTv Therapeutics Inc. Class A Common Stock

VTVT XNAS

$30.68 -0.36 (-1.16%) ▼ 15-min delayed

Open

$31.00

High

$31.92

Low

$30.68

Volume

22.5K

Market Cap

$120.84M

About vTv Therapeutics Inc. Class A Common Stock

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 26 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-31,080,000	N/A
FY 2025	$0	$-31,080,000	N/A
Q3 2025	$0	$-10,345,000	N/A
Q2 2025	$0	$-7,380,000	N/A

Related Market News

No specific coverage for VTVT yet. Check out our latest market news or earnings calendar.

Get VTVT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on vTv Therapeutics Inc. Class A Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.